Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.74 |
| ▸ | NPC1 | O15118 | 10/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.74 |
| ▸ | RAB9A | P51151 | 9/20 | 0.74 |
| ▸ | MEN1 | O00255 | 9/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 5/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761517 | 0.85 | MAPT (0.74) | MAPTNPC1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL3128570 | 0.80 | DGAT1 (0.69) | MAPTNPC1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL3387754 | 0.80 | DGAT1 (0.66) | MAPTNPC1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL3387751 | 0.79 | DGAT1 (0.65) | MAPTNPC1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL14880989 | 0.79 | MAPT (0.64) | MAPTNPC1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1304004 | 0.78 | NPC1 (0.75) | MAPTNPC1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL17252042 | 0.78 | MAPT (0.70) | MAPTNPC1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1761313 | 0.78 | SMN1; SMN2 (0.77) | MAPTNPC1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1761475 | 0.77 | MAPT (0.60) | MAPTNPC1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL14882238 | 0.76 | MAPT (0.60) | MAPTNPC1SMN1; SMN2RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2364308-B1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2364308-B1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8247418-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247418-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010057121-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057121-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | MAPT 2527/4885NPC1 3372/4885SMN1; SMN2 4522/4885 |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | MAPT 2527/4885NPC1 3372/4885SMN1; SMN2 4522/4885 |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | MAPT 2527/4885NPC1 3372/4885SMN1; SMN2 4522/4885 |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | MAPT 3514/4885NPC1 3825/4885SMN1; SMN2 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.